Physician profile
Mark N Berkowitz
NPI 1447232459
$12,266.31
in general payments reported to CMS, 2019-2025
14 companies · $279 in 2025
The $279 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.06 · 2020: $10.27 · 2021: $11K · 2023: $55.05 · 2024: $1,185 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,519.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $10,644.24 | 2019-2021 | |
| Revance Therapeutics, INC. | $1,033.43 | 2024-2025 | Daxxify |
| Abbvie INC. | $224.54 | 2023-2025 | |
| Bausch & Lomb Americas INC. | $72.53 | 2025 | Miebo, Xiidra, Vyzulta |
| Biotissue Holdings INC. | $60.00 | 2024 | |
| Apyx Medical Corporation | $53.77 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $48.57 | 2023-2024 | Cequa |
| Dompe US, INC. | $22.35 | 2025 | Oxervate |
| Regeneron Healthcare Solutions, INC. | $21.56 | 2024 | Eylea Hd |
| Oyster Point Pharma, INC. | $21.27 | 2025 | Tyrvaya, Ryzumvi |
| Acelrx Pharmaceuticals, INC. | $17.56 | 2021 | |
| Galderma Laboratories, L.P. | $16.15 | 2021 | |
| Alcon Vision LLC | $15.45 | 2019 | |
| Amgen INC. | $14.89 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Berkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.